Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro

ACS Appl Mater Interfaces. 2020 Sep 2;12(35):38873-38886. doi: 10.1021/acsami.0c07106. Epub 2020 Aug 18.

Abstract

Programmable nucleic acid nanoparticles (NANPs) with precisely controlled functional compositions can regulate the conditional activation of various biological pathways and responses in human cells. However, the intracellular delivery of NANPs alone is hindered by their susceptibility to nuclease activity and inefficient crossing of biological membranes. In this work, we optimized the internalization and therapeutic performance of several representative NANPs delivered with mesoporous silica nanoparticles (MSNPs) tailored for efficient electrostatic association with NANPs. We compared the immunostimulatory properties of different NA-MS-NP complexes formed with globular, planar, and fibrous NANPs and demonstrated the maximum immunostimulation for globular NANPs. As a proof of concept, we assessed the specific gene silencing by NA-MS-NP complexes functionalized with siRNA targeting green fluorescent protein expressed in triple-negative human breast cancer cells. We showed that the fibrous NANPs have the highest silencing efficiency when compared to globular or planar counterparts. Finally, we confirmed the multimodal ability of MSNPs to co-deliver a chemotherapy drug, doxorubicin, and NANPs targeting apoptosis regulator gene BCL2 in triple-negative breast cancer and melanoma cell lines. Overall, the combination of NANPs and MSNPs may become a new promising approach to efficiently treat cancer and other diseases via the simultaneous targeting of various pathways.

Keywords: combination therapy; doxorubicin; melanoma; mesoporous silica nanoparticles (MSNPs); nucleic acid nanoparticles (NANPs); small interfering RNA; triple-negative breast cancer.

MeSH terms

  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacology
  • Drug Carriers / chemistry*
  • Humans
  • Nanoparticles / chemistry*
  • Nucleic Acids / chemistry*
  • Porosity
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • RNA Interference
  • RNA, Small Interfering / chemistry
  • RNA, Small Interfering / metabolism
  • Silicon Dioxide / chemistry*

Substances

  • Drug Carriers
  • Nucleic Acids
  • Proto-Oncogene Proteins c-bcl-2
  • RNA, Small Interfering
  • Silicon Dioxide
  • Doxorubicin